Limits...
Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone.

Wang L, Du F, Zhang HM, Zhang WJ, Wang HX - Braz. J. Med. Biol. Res. (2015)

Bottom Line: There were no significant differences among these groups at baseline day 1 (P>0.05). cEPC levels decreased slightly at day 21 (8.2±3.3 cEPCs/μL) vs day 1 (8.4±2.9 cEPCs/μL) in good responders (P>0.05).In contrast, cEPC levels increased significantly in the other two groups (P<0.05).SDF-1α changes were closely related to changes in cEPCs.

View Article: PubMed Central - PubMed

Affiliation: Tongji Medical College, The Central Hospital of Wuhan, Department of Hematology, Huazhong University of Science and Technology, Wuhan, China.

ABSTRACT
Four cycles of chemotherapy are required to assess responses of multiple myeloma (MM) patients. We investigated whether circulating endothelial progenitor cells (cEPCs) could be a biomarker for predicting patient response in the first cycle of chemotherapy with bortezomib and dexamethasone, so patients might avoid ineffective and costly treatments and reduce exposure to unwanted side effects. We measured cEPCs and stromal cell-derived factor-1α (SDF-1α) in 46 MM patients in the first cycle of treatment with bortezomib and dexamethasone, and investigated clinical relevance based on patient response after four 21-day cycles. The mononuclear cell fraction was analyzed for cEPC by FACS analysis, and SDF-1α was analyzed by ELISA. The study population was divided into 3 groups according to the response to chemotherapy: good responders (n=16), common responders (n=12), and non-responders (n=18). There were no significant differences among these groups at baseline day 1 (P>0.05). cEPC levels decreased slightly at day 21 (8.2±3.3 cEPCs/μL) vs day 1 (8.4±2.9 cEPCs/μL) in good responders (P>0.05). In contrast, cEPC levels increased significantly in the other two groups (P<0.05). SDF-1α changes were closely related to changes in cEPCs. These findings indicate that change in cEPCs at day 21 in the first cycle might be considered a noninvasive biomarker for predicting a later response, and extent of change could help decide whether to continue this costly chemotherapy. cEPCs and the SDF-1α/CXCR4 axis are potential therapeutic targets for improved response and outcomes in MM patients.

No MeSH data available.


Related in: MedlinePlus

Representative flow cytometric analysis plots showing sequential gatingstrategy used to enumerate circulating endothelial progenitor cells (cEPCs):CD34+ and CD45-/dim cells were gated to exclude hematopoietic cells expressingCD45 antigen (A,B). C,Negative control, and D, cells co-expressing CD34 and CD309were designated as cEPCs.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4541694&req=5

f01: Representative flow cytometric analysis plots showing sequential gatingstrategy used to enumerate circulating endothelial progenitor cells (cEPCs):CD34+ and CD45-/dim cells were gated to exclude hematopoietic cells expressingCD45 antigen (A,B). C,Negative control, and D, cells co-expressing CD34 and CD309were designated as cEPCs.

Mentions: Overall, an increase was observed in cEPCs after the first cycle of chemotherapy.After 7 and 21 days, the increase in cEPCs was substantially greater than that at thebeginning, and they were consistently present. At day 7, cEPC levels increased to141% (95%CI=128-154%, P<0.01). At day 14, cEPC levels further increased to 231%(95%CI=210-253%, P<0.01). Then, at day 21, cEPC levels decreased to 188%(95%CI=163-213%, P<0.01), as shown in Figures1 and 2.


Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone.

Wang L, Du F, Zhang HM, Zhang WJ, Wang HX - Braz. J. Med. Biol. Res. (2015)

Representative flow cytometric analysis plots showing sequential gatingstrategy used to enumerate circulating endothelial progenitor cells (cEPCs):CD34+ and CD45-/dim cells were gated to exclude hematopoietic cells expressingCD45 antigen (A,B). C,Negative control, and D, cells co-expressing CD34 and CD309were designated as cEPCs.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4541694&req=5

f01: Representative flow cytometric analysis plots showing sequential gatingstrategy used to enumerate circulating endothelial progenitor cells (cEPCs):CD34+ and CD45-/dim cells were gated to exclude hematopoietic cells expressingCD45 antigen (A,B). C,Negative control, and D, cells co-expressing CD34 and CD309were designated as cEPCs.
Mentions: Overall, an increase was observed in cEPCs after the first cycle of chemotherapy.After 7 and 21 days, the increase in cEPCs was substantially greater than that at thebeginning, and they were consistently present. At day 7, cEPC levels increased to141% (95%CI=128-154%, P<0.01). At day 14, cEPC levels further increased to 231%(95%CI=210-253%, P<0.01). Then, at day 21, cEPC levels decreased to 188%(95%CI=163-213%, P<0.01), as shown in Figures1 and 2.

Bottom Line: There were no significant differences among these groups at baseline day 1 (P>0.05). cEPC levels decreased slightly at day 21 (8.2±3.3 cEPCs/μL) vs day 1 (8.4±2.9 cEPCs/μL) in good responders (P>0.05).In contrast, cEPC levels increased significantly in the other two groups (P<0.05).SDF-1α changes were closely related to changes in cEPCs.

View Article: PubMed Central - PubMed

Affiliation: Tongji Medical College, The Central Hospital of Wuhan, Department of Hematology, Huazhong University of Science and Technology, Wuhan, China.

ABSTRACT
Four cycles of chemotherapy are required to assess responses of multiple myeloma (MM) patients. We investigated whether circulating endothelial progenitor cells (cEPCs) could be a biomarker for predicting patient response in the first cycle of chemotherapy with bortezomib and dexamethasone, so patients might avoid ineffective and costly treatments and reduce exposure to unwanted side effects. We measured cEPCs and stromal cell-derived factor-1α (SDF-1α) in 46 MM patients in the first cycle of treatment with bortezomib and dexamethasone, and investigated clinical relevance based on patient response after four 21-day cycles. The mononuclear cell fraction was analyzed for cEPC by FACS analysis, and SDF-1α was analyzed by ELISA. The study population was divided into 3 groups according to the response to chemotherapy: good responders (n=16), common responders (n=12), and non-responders (n=18). There were no significant differences among these groups at baseline day 1 (P>0.05). cEPC levels decreased slightly at day 21 (8.2±3.3 cEPCs/μL) vs day 1 (8.4±2.9 cEPCs/μL) in good responders (P>0.05). In contrast, cEPC levels increased significantly in the other two groups (P<0.05). SDF-1α changes were closely related to changes in cEPCs. These findings indicate that change in cEPCs at day 21 in the first cycle might be considered a noninvasive biomarker for predicting a later response, and extent of change could help decide whether to continue this costly chemotherapy. cEPCs and the SDF-1α/CXCR4 axis are potential therapeutic targets for improved response and outcomes in MM patients.

No MeSH data available.


Related in: MedlinePlus